# Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

> **NCT05696080** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 518 (actual)

## Conditions studied

- Pneumococcal Infection

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** PCV15
- **BIOLOGICAL:** PPSV23

## Key facts

- **NCT ID:** NCT05696080
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-13
- **Primary completion:** 2024-02-16
- **Final completion:** 2024-02-16
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05696080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05696080, "Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05696080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*